Return to homepagePandemic Pact

to develop an anti-SARS-CoV-2 mAb product for prevention of severe COVID-19 in vulnerable populations in low and middle income countries

Grant number: INV-019355

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020

  • Known Financial Commitments (USD)

    $2,499,588

  • Funder

    Gates Foundation

  • Research Location

    United States of America

  • Lead Research Institution

    Columbia University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Vulnerable populations unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A

4 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections.

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants.

Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2.

Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.